Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Children's Sleep Center, Baylor College of Medicine, Houston, Texas.
Am J Med Genet A. 2019 Oct;179(10):1982-1986. doi: 10.1002/ajmg.a.61307. Epub 2019 Jul 24.
Potocki-Lupski syndrome (PTLS; MIM 610883) is a neurodevelopmental disorder caused by a microduplication, a 3.7 Mb copy number variant, mapping within chromosome 17p11.2, encompassing the dosage-sensitive RAI1 gene. Whereas RAI1 triplosensitivity causes PTLS, haploinsufficiency of RAI1 due to 17p11.2 microdeletion causes the clinically distinct Smith-Magenis syndrome (SMS; MIM 182290). Most individuals with SMS have an inversion of the melatonin cycle. Subjects with PTLS have mild sleep disturbances such as sleep apnea with no melatonin abnormalities described. Sleep patterns and potential disturbances in subjects with PTLS have not been objectively characterized. We delineated sleep characteristics in 23 subjects with PTLS who underwent a polysomnogram at Texas Children's Hospital. Eleven of these subjects (58%) completed the Child's Sleep Habits Questionnaire (CSHQ). Urinary melatonin was measured in one patient and published previously. While the circadian rhythm of melatonin in PTLS appears not to be disrupted, we identified significant differences in sleep efficiency, percentage of rapid eye movement sleep, oxygen nadir, obstructive apnea hypopnea index, and periodic limb movements between prepubertal subjects with PTLS and previously published normative data. Data from the CSHQ indicate that 64% (7/11) of parents do not identify a sleep disturbance in their children. Our data indicate that younger individuals, <10 years, with PTLS have statistically significant abnormalities in five components of sleep despite lack of recognition of substantial sleep disturbances by parents. Our data support the contention that patients with PTLS should undergo clinical evaluations for sleep disordered breathing and periodic limb movement disorder, both of which are treatable conditions.
波托茨基-卢普斯基综合征(PTLS;MIM 610883)是一种神经发育障碍,由微重复引起,微重复为 3.7Mb 拷贝数变异,定位于 17p11.2 染色体,包含剂量敏感的 RAI1 基因。虽然 RAI1 三倍敏感性导致 PTLS,但由于 17p11.2 微缺失导致的 RAI1 单倍不足导致了临床上明显不同的史密斯-马根尼斯综合征(SMS;MIM 182290)。大多数 SMS 患者存在褪黑素周期反转。PTLS 患者有轻度睡眠障碍,如睡眠呼吸暂停,但没有描述褪黑素异常。PTLS 患者的睡眠模式和潜在的睡眠障碍尚未得到客观描述。我们在德克萨斯儿童医院接受多导睡眠图检查的 23 名 PTLS 患者中描绘了睡眠特征。其中 11 名患者(58%)完成了儿童睡眠习惯问卷(CSHQ)。一名患者的尿褪黑素已被测量并发表。虽然 PTLS 中的褪黑素昼夜节律似乎没有被打乱,但我们在睡眠效率、快速眼动睡眠百分比、氧低谷、阻塞性呼吸暂停低通气指数和周期性肢体运动方面发现了 PTLS 与之前发表的正常数据之间的显著差异。CSHQ 的数据表明,64%(7/11)的父母没有发现他们孩子的睡眠障碍。我们的数据表明,尽管父母没有意识到明显的睡眠障碍,但年龄较小的(<10 岁)PTLS 患者在五个睡眠成分方面存在统计学上的异常。我们的数据支持以下观点,即 PTLS 患者应接受睡眠呼吸障碍和周期性肢体运动障碍的临床评估,这两种障碍都是可治疗的。